Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568594 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)
A Phase 1 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 1
- Development phase
- 176
- Enrollment target
NCT00568594: Completed Phase 1 study, sponsored by Novartis.
NCT00568594 is a Phase 1 study that has completed, run by Novartis. The registered enrollment target is 176 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (193% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00568594, a Phase 1 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 176 participants
- Enrollment target
Study Summary
The purpose of this study is to determine: (1) the safety and pharmacokinetics of APL180 administered as a single intravenous infusion in healthy volunteers, and (2) the safety, pharmacokinetics and pharmacodynamics of single and multiple daily intravenous infusions of APL018 in patients with CHD
Interventions
- DRUG Placebo
- DRUG APL180
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2007-11 |
| Phase | Phase 1 |
What the finished NCT00568594 record still lists
NCT00568594 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (193% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00568594 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00568594 about?
NCT00568594 is a clinical study titled "Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)". The purpose of this study is to determine: (1) the safety and pharmacokinetics of APL180 administered as a single intravenous infusion in healthy volunteers, and (2) the safety, pharmacokinetics and pharmacodynamics of single and multiple daily intravenous infusions of APL018 in patients with CHD
What is the current status of trial NCT00568594?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 176 participants. The study started on 2007-11.
What interventions are being tested in trial NCT00568594?
The interventions under investigation include: Placebo (DRUG), APL180 (DRUG).
Who is sponsoring clinical trial NCT00568594?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00568594's enrollment target sits among peer trials
176 316th of 2000 higher than 1,682 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia